Matrix metalloproteinase-3 as a marker of subclinical activity in rheumatoid arthritis patients: Relation to ultrasonographic activity

被引:4
|
作者
Hamdy, Fatma [1 ]
Morad, Nibal [1 ]
Tharwat, Samar [1 ]
Abd El-khalek, Ahmed [2 ]
Mahsoub, Nancy [3 ]
Eltoraby, Ehab [1 ]
Enein, Asmaa [1 ]
机构
[1] Mansoura Univ, Fac Med, Internal Med Dept, Rheumatol & Immunol Unit, Dakahlia, Egypt
[2] Mansoura Univ, Fac Med, Diagnost Radiol Dept, Dakahlia, Egypt
[3] Mansoura Univ, Fac Med, Clin Pathol Dept, Dakahlia, Egypt
来源
EGYPTIAN RHEUMATOLOGIST | 2022年 / 44卷 / 03期
关键词
Rheumatoid arthritis; Remission; Subclinical activity; Matrix metalloproteinase-3; Sonographic activity; DISEASE-ACTIVITY;
D O I
10.1016/j.ejr.2021.12.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Rheumatoid arthritis (RA) isa chronic disease which may result in progressive joint destruc-tion even with clinical remission. Ultrasound (US) can detect subclinical disease activity and matrix met-alloproteinase 3 (MMP-3) has a role in disease activity in RA. Aim of the work: To evaluate the level of MMP-3 in RA patients and its ability to predict sonographic activ-ity in patients with clinical remission or low disease activity (LDA). Patients and methods: This study included 45 RA patients with a disease activity score (DAS28) <3.2 and 45 matched healthy control. US evaluation using modified German US7 score was performed and accord-ingly patients were classified into those with sonographic remission (grey scale 0-1) or activity. MMP-3 level was assessed by enzyme-linked immunosorbent assay. Results. The mean age of the patients was 45 +/- 9.5 years and 86.7% were females. Sonographic remission was achieved in 20 (44.4 %) patients. There was a significant difference in serum MMP-3 between patients and control (17 +/- 4.5 vs 6.3 +/- 2.2 ng/ml; p < 0.0001). There was no difference between patients with clinical remission (n = 37) and those with LDA (n = 8). Serum MMP-3 tended to be higher in patients with sono-graphic activity than in those with sonographic remission (18 +/- 5.3 vs 15.6 +/- 2.8 ng/ml; p = 0.3). Serum MMP-3 significantly correlated with erythrocyte sedimentation rate (p = 0.002) and synovitis score (p = 0.002). Conclusion: Serum MMP-3 was higher in RA patients than in control and was associated with the ultra -sound synovitis score. However, serum MMP-3 was not able to differentiate patients with sonographic remission from those with subclinical activity. (c) 2022 Egyptian Society of Rheumatic Diseases. Publishing services provided by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:261 / 265
页数:5
相关论文
共 50 条
  • [41] Baseline serum level of matrix metalloproteinase-3 as a biomarker of progressive joint damage in rheumatoid arthritis patients
    Galil, Sahar Mahfouz Abdel
    El-Shafey, Abeer Mohamed
    Hagrass, Hoda A.
    Fawzy, Faten
    El Sammak, Ahmed
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2016, 19 (04) : 377 - 384
  • [42] Serum Matrix Metalloproteinase-3 as a Noninvasive Biomarker of Histological Synovitis for Diagnosis of Rheumatoid Arthritis
    Ma, Jian-Da
    Zhou, Jing-Jing
    Zheng, Dong-Hui
    Chen, Le-Feng
    Mo, Ying-Qian
    Wei, Xiu-ning
    Yang, Li-Juan
    Dai, Lie
    MEDIATORS OF INFLAMMATION, 2014, 2014
  • [43] Serum levels of matrix metalloproteinase-3 in rheumatoid arthritis (RA) follow-up.
    Pozzi, MR
    Banfi, E
    Redaelli, C
    Montani, N
    Mariani, E
    D'Angelo, L
    Stabilini, R
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S184 - S184
  • [44] Relationship between matrix metalloproteinase-3 serum level and pulmonary artery systolic pressure in patients with rheumatoid arthritis
    Tetsuro Sugiura
    Mikio Kamioka
    Shigeo Yamanaka
    Taisuke Hisahara
    Yoko Hirakawa
    Yoshihisa Matsumura
    Heart and Vessels, 2018, 33 : 191 - 197
  • [45] Comment on 'Baseline serum level of matrix metalloproteinase-3 as a biomarker of progressive joint damage in rheumatoid arthritis patients'
    Zhao, Ming-Dong
    Yuan, Feng-Lai
    Li, Xia
    Xiong, Min
    Cai, Guo-Ping
    Xu, Ji
    Zhang, Xin-Chao
    Yin, Wang-Ping
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2017, 20 (11) : 1794 - 1794
  • [46] CLINICAL SIGNIFICANCE OF SERUM MATRIX METALLOPROTEINASE-3 NORMALISATION IN RHEUMATOID ARTHRITIS PATIENTS WITH ANTI-TNF THERAPY
    Hattori, Y.
    Kaneko, A.
    Kida, D.
    Takahashi, N.
    Ishikawa, H.
    Kanda, H.
    Sato, T.
    Kojima, T.
    Ishiguro, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 487 - 488
  • [47] Effects of Alpha-Lipoic Acid Supplementation on Inflammatory Biomarkers and Matrix Metalloproteinase-3 in Rheumatoid Arthritis Patients
    Mirtaheri, Elham
    Gargari, Bahram Pourghassem
    Kolahi, Sousan
    Dehghan, Parvin
    Asghari-Jafarabadi, Mohammad
    Hajalilou, Mehrzad
    Novin, Zahra Shakiba
    Abbasi, Mehran Mesgari
    JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, 2015, 34 (04) : 310 - 317
  • [48] Steroid therapy and renal dysfunction are independently associated with serum levels of matrix metalloproteinase-3 in patients with rheumatoid arthritis
    Hattori, Yosuke
    Kida, Daihei
    Kaneko, Atsushi
    MODERN RHEUMATOLOGY, 2018, 28 (02) : 242 - 248
  • [49] Relationship between matrix metalloproteinase-3 serum level and pulmonary artery systolic pressure in patients with rheumatoid arthritis
    Sugiura, Tetsuro
    Kamioka, Mikio
    Yamanaka, Shigeo
    Hisahara, Taisuke
    Hirakawa, Yoko
    Matsumura, Yoshihisa
    HEART AND VESSELS, 2018, 33 (02) : 191 - 197
  • [50] Effect of oleanolic acid on the activity, secretion and gene expression of matrix metalloproteinase-3 in articular chondrocytes in vitro and the production of matrix metalloproteinase-3 in vivo
    Kang, Dong-Geun
    Lee, Hyun Jae
    Kim, Kun Tae
    Hwang, Sun-Chul
    Lee, Choong Jae
    Park, Jin Sung
    KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY, 2017, 21 (02): : 197 - 204